On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
-
BUSINESS Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
-
REGULATORY 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
-
REGULATORY MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
-
REGULATORY Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
February 16, 2026
-
REGULATORY DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
-
BUSINESS FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
-
BUSINESS Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
-
BUSINESS Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
-
REGULATORY LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
-
COMMENTARY Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
-
ORGANIZATION Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
-
BUSINESS Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
-
BUSINESS Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
February 6, 2026
-
COMMENTARY Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
-
BUSINESS Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
-
BUSINESS Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
-
ORGANIZATION FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
-
BUSINESS AstraZeneca Names Andy Barnett as New Japan President
February 3, 2026
-
BUSINESS Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement
February 2, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…